Women's views on postpartum testing for type 2 diabetes after gestational diabetes: Six month follow-up to the DIAMIND randomised controlled trial

Emer Van Ryswyk, Philippa Middleton, W. Hague, Caroline Crowther

    Research output: Contribution to journalArticlepeer-review

    16 Citations (Scopus)

    Abstract

    Background This study assessed the views of the women who participated in the DIAMIND randomised trial of postpartum SMS reminders to test for type 2 diabetes after gestational diabetes (GDM) on their preferred type of postpartum reminder system and barriers and facilitators to completion of postpartum diabetes testing. Method A written questionnaire was sent to women with recent GDM who participated in the DIAMIND trial (n = 276) via post or email at six months after the birth of their baby. Results 208 women (75%) returned the study questionnaires. Preferred postpartum reminder types were: SMS (67%), email (17%), postal (12%) and voice call (1%). Women who had not yet completed an OGTT indicated that they planned to undertake one in the future (61%). Common barriers to postpartum OGTT completion included: not having enough time (73%), inadequate childcare (30%), and a need to focus on the health of the baby (30%). The most common facilitator was having a shorter test (33%). Conclusions Improved childcare quality and access as well as more research into a shorter, more convenient test procedure for type 2 diabetes screening are needed. Reminder systems for postpartum diabetes screening should be electronic where possible.

    Original languageEnglish
    Pages (from-to)91-102
    Number of pages12
    JournalPrimary Care Diabetes
    Volume10
    Issue number2
    DOIs
    Publication statusPublished - 1 Apr 2016

    Keywords

    • Gestational diabetes mellitus
    • Postpartum care
    • Screening
    • Type 2 diabetes
    • Women's views

    Fingerprint Dive into the research topics of 'Women's views on postpartum testing for type 2 diabetes after gestational diabetes: Six month follow-up to the DIAMIND randomised controlled trial'. Together they form a unique fingerprint.

    Cite this